Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
DOI: https://doi.org/10.2147/CEOR.S391413
2023-02-23
ClinicoEconomics and Outcomes Research
Abstract:Harpreet Singh, 1 Liam Wilson, 2 Tom Tencer, 3 Jinender Kumar 3 1 Health Economics & Market Access (HEMA), Amaris Consulting Ltd, Toronto, ON, Canada; 2 Health Economics & Market Access (HEMA), Amaris Consulting Ltd, Shanghai, People's Republic of China; 3 Bristol Myers Squibb, Princeton, NJ, USA Correspondence: Jinender Kumar, Global HEOR, Bristol Myers Squibb, 100 Nassau Park Blvd &num300, Princeton, NJ, 08540, USA, Tel +1-609-302-7630, Email Background: Currently approved biologic therapies for moderate-to-severe ulcerative colitis have well-established efficacy. However, many patients fail to respond or lose response, leading to dose escalation or treatment switching. Objective: We sought to identify real-world evidence on dose escalation and treatment switching and associated clinical and economic outcomes among adults with ulcerative colitis treated with infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, or tofacitinib. Methods: We conducted a systematic search of Embase, MEDLINE (up to 26 August 2020), and conference proceedings (2017− 2020) for studies in adults with ulcerative colitis to assess clinical response and remission, colectomy, adverse events, and economic outcomes related to dose escalation and treatment switching. Results: In 56 studies, dose escalation and treatment switching involving infliximab and/or adalimumab were most frequently investigated. Rates of clinical response after dose escalation were 20– 95% (1.8– 36 months), clinical remission rates were 10– 94% (1.8– 36 months), colectomy rates were 0– 33% (12– 38 months), and adverse event rates were 0– 18%. Treatment switching rates in 21 studies were 4– 70% over 3– 62 months, with switch due to loss of response rates of 4– 35% over 12– 62 months (7 studies). Up to 35% of patients underwent colectomy 12− 120 weeks after switching, and 13– 38% experienced adverse events. Data relating to economic outcomes were limited to tumor necrosis factor inhibitors, but demonstrated increased direct costs associated with both dose escalation and treatment switching. Conclusion: Dose escalation and treatment switching are common with existing therapies. However, clinical response and remission rates vary, and a proportion of patients fail to achieve optimal clinical and economic outcomes. This highlights the need for more efficacious and durable treatments for patients with moderate-to-severe ulcerative colitis. Keywords: ulcerative colitis, real-world evidence, systematic literature review, biologic therapies, tofacitinib Although biologic therapies are effective treatments for patients with moderate-to-severe ulcerative colitis, many fail to respond or lose response over time. These patients may then receive higher doses or more frequent doses of their therapy (called dose escalation) or may switch treatments. We performed a systematic literature review to gather real-world evidence of clinical and economic outcomes for patients who experience dose escalation or treatment switching, including rates of clinical response (improvement in disease activity), clinical remission (little or no disease activity visible endoscopically), colectomy (a surgical procedure to remove all or part of colon), and adverse events, as well as direct healthcare costs. The treatments included in the search were the biologic therapies infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab and the small molecule tofacitinib. We found 56 studies reporting outcomes and treatment patterns for these treatments, with the most data for infliximab and adalimumab. Clinical outcomes varied widely, with rates of clinical response after dose escalation of 20–95%, clinical remission rates of 10–94%, colectomy rates up to 33%, and adverse event rates up to 18%. Between 4% and 35% of patients switched treatments; of these, up to 35% underwent colectomy and 13–38% experienced adverse events. Direct costs were higher after both dose escalation and treatment switching. Since clinical outcomes were so varied and costs were higher for patients experiencing these treatment strategies, the study suggests a need for more effective and durable treatments for patients with moderate-to-severe ulcerative colitis. Ulcerative colitis (UC) is a chronic, relapsing-remitting disease characterized by inflammation of the rectal and colonic mucosa. 1 UC is a major form of inflammatory bowel disease (IBD), 2 and its worldwide incidence and prevalence are rising. 3 The Montreal classification categorizes UC into 3 subgroups defined by disease extent: ulcerative proctitis (rectal involvement only), left-sided or distal UC (inflammation limited to a proportion of the co -Abstract Truncated-